LFVN vs. RZLT, BMEA, TERN, VRCA, AMRN, NLTX, VTYX, XERS, STTK, and ORGO
Should you be buying LifeVantage stock or one of its competitors? The main competitors of LifeVantage include Rezolute (RZLT), Biomea Fusion (BMEA), Terns Pharmaceuticals (TERN), Verrica Pharmaceuticals (VRCA), Amarin (AMRN), Neoleukin Therapeutics (NLTX), Ventyx Biosciences (VTYX), Xeris Biopharma (XERS), Shattuck Labs (STTK), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical preparations" industry.
LifeVantage (NASDAQ:LFVN) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.
35.3% of LifeVantage shares are owned by institutional investors. Comparatively, 83.0% of Rezolute shares are owned by institutional investors. 6.8% of LifeVantage shares are owned by company insiders. Comparatively, 20.8% of Rezolute shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
LifeVantage has a net margin of 1.75% compared to Rezolute's net margin of 0.00%. LifeVantage's return on equity of 27.02% beat Rezolute's return on equity.
Rezolute has a consensus price target of $9.67, suggesting a potential upside of 66.95%. Given Rezolute's higher probable upside, analysts clearly believe Rezolute is more favorable than LifeVantage.
LifeVantage has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than LifeVantage, indicating that it is currently the more affordable of the two stocks.
LifeVantage received 164 more outperform votes than Rezolute when rated by MarketBeat users. Likewise, 77.82% of users gave LifeVantage an outperform vote while only 76.00% of users gave Rezolute an outperform vote.
LifeVantage has a beta of 0.87, suggesting that its stock price is 13% less volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.3, suggesting that its stock price is 30% more volatile than the S&P 500.
In the previous week, Rezolute had 5 more articles in the media than LifeVantage. MarketBeat recorded 5 mentions for Rezolute and 0 mentions for LifeVantage. Rezolute's average media sentiment score of 0.52 beat LifeVantage's score of 0.00 indicating that Rezolute is being referred to more favorably in the news media.
Summary
LifeVantage beats Rezolute on 9 of the 16 factors compared between the two stocks.
Get LifeVantage News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFVN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LifeVantage Competitors List
Related Companies and Tools
